Linked Life Data

3148649

Source:http://linkedlifedata.com/resource/pubmed/id/3148649

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1989-5-3
pubmed:abstractText
We have assessed the beneficial effects of administering a short course of an agonist of LHRH (Buserelin) in vitro fertilisation. 274 cycles were treated with CC-HMG, 159 were treated with HMG alone and 253 by Buserelin-HMG. These were compared retrospectively. The use of a short course of Buserelin lowered significantly the rate of failed treated cycles (7% instead of 19% when it was used with CC-HMG and 27% when used with HMG). This made it possible to administer hCG in all cases in the programme (100% as against 69% and 89% respectively for CC-HMG and HMG without Buserelin), and increase significantly the number of oocytes that could be recovered and the number of embryos available for transfer. The overall number of pregnancies per cycle treated is significantly raised when Buserelin is used with HMG (20.4% as against 13.5% for CC-HMG and HMG). The number of pregnancies that progressed, on the other hand, was similar when the cycle was stimulated with HMG alone (10.6%) or with Buserelin-HMG (10.6%).
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0368-2315
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1081-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
[The beneficial effects of short-term administration of a LHRH agonist (buserelin) in in vitro fertilization].
pubmed:affiliation
Services d'Obstétrique et de Gynécologie, Cliniques Universitaires Saint-Luc, Université de Louvain, Bruxelles.
pubmed:publicationType
Journal Article, Comparative Study, English Abstract